Attention www.globalkeysolutions.net is now www.keypedia.com, read the full press release here.
KeyPedia LogoKeyPedia Icon
  1. Home
  2. /
  3. Records
  4. /
  5. Warning Letter
  6. /
  7. Supergoop!
WARNING LETTER
•Supergoop!•May 2, 2025

Supergoop! – FDA Warning Letter, May 2, 2025

Record Details

The FDA issued a warning letter to Supergoop, located at 200 East Grayson Suite #110, San Antonio, TX, on August 6, 2025, following a review conducted on May 2, 2025. The review focused on the labeling and marketing of their product, "Supergoop! PLAY SPF 50 BODY MOUSSE," available for purchase online and through social media platforms. The FDA identified the product as a drug under the Federal Food, Drug, and Cosmetic Act (FD&C Act) because it is intended for the prevention of sunburn, thus affecting the body"s structure or function.

The main violation highlighted is that the product is marketed as an over-the-counter (OTC) sunscreen drug without an FDA-approved application, as required under section 505 of the FD&C Act. The product does not conform to the conditions of the applicable OTC monograph for sunscreen drug products, specifically because it is in a mousse form, which is not authorized under current FDA regulations for sunscreens.

The FDA requires Supergoop to address these violations by ensuring compliance with federal law and FDA regulations. The company must submit a written response within 15 working days detailing the corrective actions taken, including documentation. Failure to comply may result in legal actions such as product seizure or injunction. Supergoop is advised to send their response to the FDA"s Office of Unapproved Drugs and Labeling Compliance via email, including the unique identifier “711018” in the subject line.

Company
Supergoop!
Inspection date
May 2, 2025
Product type
Drugs
Office
Center for Drug Evaluation and Research
Person
  • Tina Smith (Director)
View Company Profile

ID · 62fa10eb-1d3d-4a95-a4b2-adda754f1cb9

Violation Codes10
21 U.S.C. 331(a)21 U.S.C. 321(g)(1)(B)21 U.S.C. 321(g)(1)(C)21 CFR 20721 CFR 201.12821 U.S.C. 35521 U.S.C. 355h21 U.S.C. 352(ee)FD&C Act 505FD&C Act 505G

Full citation text and observation details available on the Dashboard.

Your cart

Your cart is empty.

Browse public document pages and click Buy this document. We'll ask for your email at checkout, no account needed up front.

Browse documents

Discuss this record with AI

KeyPedia

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore Supergoop!
KeyPedia
Regulatory Data Transformed
Stay in the loop

KRA score changes, company updates and news. About monthly, unsubscribe anytime.

Contact
New York Office:
370 Jay Street 7th Floor
Brooklyn, NY 11201
Scranton Office:
Scranton Enterprise Center, Suite 217
201 Lackawanna Avenue
Scranton, PA, 18503
🇺🇸+1 917-789-5099
🇪🇺+48 532-447-507
info@keypedia.com
Quick Links
HomePlatform OverviewMedia
KeyPedia™ Lite
Browse HubDatabase DirectoryRecordsCompaniesOfficesPeopleCareersAbout UsFounding TeamMeet Our ExpertsPartners
Legal & Ethics
Privacy PolicyTerms of ServiceOur Values & MissionCode of Ethics & AI Policy
©2026 KeyPedia™ | Global Key Solutions Corp. All rights reserved.